Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clemizole hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Epygenix Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100
Details : This Phase 2 study will confirm the efficacy and safety of EPX-100 with children suffering from Dravet Syndrome. The Company is now recruiting patients for this clinical study, collaborated with GreenLight Clinical.
Brand Name : EPX-100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 17, 2020
Lead Product(s) : Clemizole hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Epygenix Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?